The density and spatial tissue distribution of CD8⁺ and CD163⁺ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors.

ABSTRACT:

Background

Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons still needing to be elucidated. As the patient immune activity contributes to treatment clinical benefit, the pre-existing level of immunity at tumor site may provide biomarkers of disease outcome to therapy. Here we investigated whether assessing the density and spatial tissue distribution of key immune cells in the tumor microenvironment could identify patients predisposed to respond to MAPK inhibitors.

Methods

Pretreatment tumor biopsies from a total of 213 patients (158 for the training set and 55 for the validation set) treated with BRAF or BRAF/MEK inhibitors within the Italian Melanoma Intergroup were stained with selected immune markers (CD8, CD163, β-catenin,

SUBMITTER: Massi D 

PROVIDER: S-EPMC6858711 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature